Stock screener

CHRS

Conviction 28HealthcareScan · Mon, Aug 10, 2026
CHRS$1.24-2.36%
ResistanceSupportVol 14
63 bars
Vol MA14 982.17K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Coherus Oncology, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.coherus.com
Price1.24
Change-2.36%
Gap+3.54%
Rel volume3.76×
Avg volume836.39K
Avg $ vol1.13M
SMA 201.41
SMA 501.45
SMA 2001.59
Price vs 50-14.69%
Price vs 200-21.93%
MA stackbearish
50/200 cross
Supertrenddown · 1.59
RSI (14)34
MACD hist-0.02
MACD crossbear · 2d
Stoch %K / %D28 / 32
ADX (14)14
+DI / −DI13 / 29
RSI divergence
MACD divergence
ATR %+7.95%
ADR %6.07%
52w high2.51
52w low0.8209
From 52w high-50.60%
Above 52w low+51.05%
New 52w highNo
SqueezeOn · 4d
Bollinger width19.19%
%B-0.12
Donchian pos27.66%
Donchian high1.53
Donchian low1.13
AVWAP (52w high)1.74
vs AVWAP high-28.68%
AVWAP (52w low)1.63
vs AVWAP low-24.02%
OBV trendDown
Chaikin MF (20)-0.34
Today vs 20d3.76×
Avg vol (14d)982.17K
Avg vol (20d)836.39K
Avg $ vol (20d)1.13M
Market cap191.58M
RS 3m (vs SPY)-33.54%
RS 6m (vs SPY)-53.35%
RS line new highNo
Trend template2/8
Technical rank8.8
1 week-13.89%
1 month-19.48%
3 months-29.14%
6 months-42.06%
1 year+40.29%
YTD-9.49%
P/E1.14
P/B3.15
P/S
P/FCF-1.38
EPS1.43
Div yield
ROE276.18%
ROA87.89%
Debt/Eq1.21
Current1.77
EV/EBITDA-1.01
Gross margin
Net margin
Rev growth-100.00%
EPS growth489.41%
Price target
Target upside
Analyst rating
Institutional
Ent. value182.32M
Revenue1.4M
Net income-20.63M
Gross profit
Free cash flow-138.8M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out154.25M
Employees145
ListedThu, Nov 6, 2014
Free float106.86M
Float %71.5%
Short interest23.89M
Days to cover24.4d
Short volume42.4%
Squeeze score82 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction28 / 100
Pattern quality
Tech rank8.8 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance1.64
Support1.23
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CHRS

All disclosures →
No recent disclosed trades by Congress in CHRS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CHRS · 10 buys

InsiderSideShares
O'Donnell-Tormey Jill
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Wahlstrom Mats
Director · Common Stock · 2026-06-05
Grant30K
Karachun Rita A
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Wahlstrom Mats
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Newcomer Lee Nisley
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Satvat Ali J.
Director · Common Stock · 2026-06-05
Grant30K
Newton Charles W.
Director · Common Stock · 2026-06-05
Grant30K
Satvat Ali J.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K
Ryan Michael Lee
Director · Common Stock · 2026-06-05
Grant30K
Newton Charles W.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant60K

SEC filings

EDGAR filings in CHRS · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.